NCT07327411 2026-01-08
Cetuximab β Combined With PRaG Regimen in the Treatment of EGFR-positive Advanced Refractory Solid Tumors
Second Affiliated Hospital of Soochow University
Phase 2 Not yet recruiting
Clinical Trials
12 trialsNCT07159191 2025-09-08
Envafolimab Combined With Axitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma
Peking Union Medical College Hospital
Phase 2 Not yet recruiting
NCT07142863 2025-08-27
Envafolimab Combined With Neoadjuvant Chemotherapy Treat Stage IIb Resectable Osteosarcoma Patients
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Phase 2 Not yet recruiting
NCT06772233 2025-07-31
A Study of Regorafenib Combined With Envafolimab for Metastatic Gastrointestinal Stromal Tumors With Kit Gene Exon 17 Mutation That Failed Standard Treatment
Peking University
Phase 2 Not yet recruiting
NCT07003815 2025-06-04
Envafolimab With Chemotherapy and Simvastatin in Advanced Biliary Tract Cancer
Tongji Hospital
Phase 2 Not yet recruiting
NCT06692491 2024-11-18
SPRING
Peking University Shenzhen Hospital
Phase 2 Not yet recruiting
NCT04910386 2024-08-14
Multicenter Phase 2 Study of Envafolimab in Biliary Tract Cancers
3D Medicines
Phase 2 Not yet recruiting
NCT06010667 2023-08-24
A Prospective, Randomized Controlled Study of Cyclophosphamide, Bevacizumab With or Without Envafolimab in Recurrent Epithelial Ovarian Cancer (EOC), Fallopian Tube Cancer, and Primary Peritoneal Cancer
Hebei Medical University Fourth Hospital
Not yet recruiting
NCT05969847 2023-08-01
TRACE-LE
Fujian Medical University Union Hospital
Phase 2 Not yet recruiting
NCT05879796 2023-05-30
Envafolimab Combined With Endostar and Concurrent Chemoradiotherapy for Locally Advanced Primary Cervical Cancer
Peking University Third Hospital
Not yet recruiting
NCT05799469 2023-04-05
Study of Chemoradiotherapy With Envafolimab For The Treatment of Locally Advanced Cervical Cancer
Chongqing University Cancer Hospital
Phase 2 Not yet recruiting
NCT05645094 2022-12-13
Neoadjuvant Envafolimab in Resectable and Locally Advanced MSI-H/dMMR Rectal Cancer
Fudan University
Not yet recruiting